Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
| Price | $6.99 |
|---|---|
| Market cap | $698.38M |
| Sector | Healthcare |
| Industry | Medical - Care Facilities |
| Exchange | NASDAQ |
| 52-week range | 2.32-7.13 |
| Beta | 0.44 |
Explore STLN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.